HSandM Magazine

Menu
  • Home
  • About
  • Headlines
  • Top Articles
    • Executive Spotlights
    • Round Tables
    • Industry Trends
    • Talent Trends
    • Great Minds
    • Innovation Showcase
    • Top Industry Lists
    • Why I Work in Healthcare
  • Submit an Innovation!
  • Advertise
  • Agency Directory
  • FREE SUBSCRIPTION!
Menu

HSandM Magazine

Search

hsandm

Latest stories

Headlines

Terremoto Biosciences Launches With $75 Million Series A Financing and Mission to Discover and Develop Groundbreaking Covalent Medicines

Headlines

1 Shares

Castle Creek Biosciences Raises $112.8 Million to Advance Novel Gene Therapies and Expand Pipeline

Headlines

Genexine Appoints Industry Veteran Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

More stories

  • Headlines
    in Headlines

    Terremoto Biosciences Launches With $75 Million Series A Financing and Mission to Discover and Develop Groundbreaking Covalent Medicines

    May 25, 2022, 3:39 pm

  • Headlines
    in Headlines

    Castle Creek Biosciences Raises $112.8 Million to Advance Novel Gene Therapies and Expand Pipeline

    May 25, 2022, 3:15 pm

  • Headlines
    in Headlines

    Genexine Appoints Industry Veteran Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

  • Headlines
    in Headlines

    Britt Meelby Jensen appointed new CEO of Ambu

    May 19, 2022, 3:24 pm

  • Headlines
    in Headlines

    Laekna Therapeutics Raises $61 Million in Series D financing

    May 18, 2022, 3:53 pm

  • Headlines
    in Headlines

    Johnson & Johnson Appoints Thibaut Mongon as CEO Designate of Planned New Consumer Health Company

    May 11, 2022, 4:01 pm

  • Headlines
    in Headlines

    MOMA Therapeutics Announces $150 Million Series B Financing

    May 10, 2022, 3:57 pm

  • Headlines
    in Headlines

    Pfizer buys its way into migraine with $11.6B Biohaven Pharma acquisition

    May 10, 2022, 2:49 pm

  • Headlines
    in Headlines

    Aspen Neuroscience Announces $147.5 Million Series B Financing, Led by GV, LYFE Capital and Revelation Partners

  • Headlines
    in Headlines

    Insulet Announces CEO Transition

    May 5, 2022, 2:54 pm

  • Headlines
    in Headlines

    Cell MedX Corp. Appoints Mr. Dwayne Yaretz as CEO and Director

    April 27, 2022, 3:51 pm

  • Headlines
    in Headlines

    Pheast Raises $76M in Series A Funding to Train the Immune System to Feast on Cancer

    April 26, 2022, 4:39 pm

Load More
Congratulations. You've reached the end of the internet.

Trending Now

  • Headlines

    394 Views0 Comments

    in Headlines

    Terremoto Biosciences Launches With $75 Million Series A Financing and Mission to Discover and Develop Groundbreaking Covalent Medicines

    South San Francisco, CA., May 25, 2022 (BUSINESS WIRE) –Terremoto Biosciences, a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines, today announced it has raised $75 million in a Series A financing. The round was co-led by OrbiMed and Third Rock Ventures. Proceeds from the financing will be used to advance Terremoto’s lysine-targeted covalency platform and develop best-in-class therapies against known drug targets, as well as first-in-class medicines against the previously undruggable. More

    by hsandm May 25, 2022, 3:39 pm

    Read More

  • Headlines

    1 Shares499 Views0 Comments

    in Headlines

    Castle Creek Biosciences Raises $112.8 Million to Advance Novel Gene Therapies and Expand Pipeline

    Exton, PA, May 25, 2022 (PRNewswire) —  Castle Creek Biosciences, Inc., a late-stage cell and gene therapy company using two lentiviral platforms to develop and commercialize therapies for genetic diseases, today announced an oversubscribed and upsized preferred stock financing of $112.8 million. More

    by hsandm May 25, 2022, 3:15 pm

    Read More

  • Headlines

    511 Views0 Comments

    in Headlines

    Genexine Appoints Industry Veteran Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

    Seoul, KR., May 24, 2022 — (BUSINESS WIRE) –Genexine (KOSDAQ: 095700) a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, announced the appointment of Neil Warma as its President and Chief Executive Officer. Mr. Warma who has over 25 years of experience as a global entrepreneur, company builder and successful CEO will lead Genexine onto the world stage with a focus on advancing Genexine’s key products to market, expanding its pipeline and focusing on global drug development. More

    by hsandm May 24, 2022, 3:47 pm

    Read More

  • Headlines

    886 Views0 Comments

    in Headlines

    Britt Meelby Jensen appointed new CEO of Ambu

    Columbia, MD, May 19, 2022 (Globe Newswire) — The Board of Directors of Ambu A/S has appointed Britt Meelby Jensen as new Chief Executive Officer (CEO). Britt Meelby Jensen has served as board member of Ambu since 2019, a position she will step down from when she takes over the position as CEO on 20 May 2022 and replaces Juan Jose Gonzalez who will leave Ambu after three years and support the new CEO in the transition as needed. More

    by hsandm May 19, 2022, 3:24 pm

    Read More

  • Headlines

    1k Views0 Comments

    in Headlines

    Laekna Therapeutics Raises $61 Million in Series D financing

    Shanghai and Warren, N.J., May 18, 2022 (PRNewswire) —  Laekna Therapeutics (“Laekna”), a clinical-stage global biotechnology company dedicated to developing next generation medicines to treat cancer and liver diseases, announced that it has raised $61 million in Series D financing led by CS Capital with support from Worldstar, and Infinity Capital. Yanchuang Capital as the existing investor continued to support the company with additional funding. More

    by hsandm May 18, 2022, 3:53 pm

    Read More

  • Headlines

    1.1k ViewsComments Off on Johnson & Johnson Appoints Thibaut Mongon as CEO Designate of Planned New Consumer Health Company

    in Headlines

    Johnson & Johnson Appoints Thibaut Mongon as CEO Designate of Planned New Consumer Health Company

    New Brunswick, N.J., May 11, 2022 (PRNewswire) —  Johnson & Johnson (the “Company”) (NYSE: JNJ) today announced the appointment of Thibaut Mongon as Chief Executive Officer Designate and Paul Ruh as Chief Financial Officer Designate of the future, listed New Consumer Health Company. More

    by hsandm May 11, 2022, 4:01 pm

    Read More

Categories

  • Agency Directory
  • Digital Magazine
  • Editorial Board
  • Executive Spotlight
  • Great Minds
  • Headlines
  • Industry Trends
  • Innovation Showcase
  • Leadership
  • Motivideos
  • Round Table
  • Talent Trends
  • Top Industry Lists
  • Uncategorized
  • Why I Work in Healthcare

© 2022 by CL Media, Inc.

  • Home
  • Contact us
  • Privacy Policy
  • Terms of Use
  • Sign Up!
Back to Top
Close
  • Home
  • About
  • Headlines
  • Top Articles
    • Executive Spotlights
    • Round Tables
    • Industry Trends
    • Talent Trends
    • Great Minds
    • Innovation Showcase
    • Top Industry Lists
    • Why I Work in Healthcare
  • Submit an Innovation!
  • Advertise
  • Agency Directory
  • FREE SUBSCRIPTION!
  • facebook
  • twitter
  • instagram
  • pinterest
  • youtube

Log In

Sign In

Forgot password?

Forgot password?

Enter your account data and we will send you a link to reset your password.

Back to Login

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

To use social login you have to agree with the storage and handling of your data by this website. %privacy_policy%

Accept

Add to Collection

  • Public collection title

  • Private collection title

No Collections

Here you'll find all collections you've created before.